Kinnate Biopharma upsizes IPO and prices above range at $20 a share

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 4, 2020 at 11:12 AM.

  1. #1 cafead, Dec 4, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Kinnate Biopharma KNTE, -5.03% upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 million it originally planned, to raise $240 million. Kinnate has applied to list on Nasdaq, under the ticker "KNTE."

    article source
     
    Quote

Reply to Thread